Login / Signup

Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotype.

Birgit M WollmannElisabet StørsetMarianne Kristiansen KringenEspen MoldenRobert Løvsletten Smith
Published in: European journal of clinical pharmacology (2023)
The M414-to-solanidine MR is an excellent predictor of the CYP2D6 PM phenotype. By measuring solanidine and metabolites using liquid chromatography-mass spectrometry in patient serum samples, CYP2D6 PMs can easily be identified, hence facilitating the implementation of precision dosing in clinical practice.
Keyphrases